References of "DE PRIJCK, Bernard"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailComparison of combined whole-body 18F-NAF and 18F-FDG PET/CT versus MRI for the detection of myeloma lesions
WITHOFS, Nadia ULiege; COUSIN, François ULiege; TANCREDI, Tino et al

Conference (2016, June 14)

Objectives Imaging requirements for the diagnosis of multiple myeloma (MM) recently changed and 蠅 1 osteolytic bone destruction (蠅 5 mm in size) seen on whole-body (WB) low-dose computed tomography (ldCT ... [more ▼]

Objectives Imaging requirements for the diagnosis of multiple myeloma (MM) recently changed and 蠅 1 osteolytic bone destruction (蠅 5 mm in size) seen on whole-body (WB) low-dose computed tomography (ldCT) or positron emission tomography combined with CT (PET/CT) does fulfill the criteria for bone disease. The present work assessed the lesion detection rate of WB combined [18F]NaF and [18F]FDG PET/CT versus ldCT alone and MRI in patients with newly diagnosed MM. Methods Patients with newly diagnosed MM, prospectively included, underwent WB (from vertex to toes) XR, MRI and combined [18F]NaF and [18F]FDG PET/CT (median delay between scans: 6 days). PET/CT scans were acquired after injection of 134 ± 13 MBq [18F]NaF and 249 ± 18 MBq [18F]FDG (median uptake time: 64 min). The ldCT (3 mm slice thickness; 120 kV; 50-80 mAs) followed by PET emission scan (90 seconds per bed position) were performed. The MR images were acquired in coronal planes in T1-weighted and T2-weighted short-tau inversion recovery. Diffusion-weighted with background suppression images were acquired in the axial plane and reconstructed on coronal planes. PET and LdCT images were reviewed by 2 experienced nuclear medicine physicians and 1 radiologist to detect focal lesions (FLs) and/or diffuse bone marrow involvement. The focal areas of visually detectable increased tracers’ uptake were considered as PET FLs. The MR, ldCT alone and XR images were analyzed by 3 radiologists blinded to each other and to PET/CT results. The FLs were classified according to their location: pelvis, skull, limbs, spine, ribs and one location including the sternum, scapula and clavicles. The McNemar’s test was used to compare the detection rate of each technique and the Kruskal-Wallis test was used to estimate a relationship between the detection rate and the size of FLs measured with ldCT. Results Out of 14 patients initially included, two were excluded (one for a delay > 40 days with XR and one who experienced claustrophobia during MRI acquisition). Twelve myeloma patients (median age 64y) with stage 1 (n = 4), 2 (n = 5) or 3 (n = 3) were included in the analyses. The pattern of bone marrow involvement was focal (n = 7) or combined diffuse and focal (n = 5). Per patient, 1-3 FL (n = 4), 4-10 FLs (n = 2) or > 10 FLs (n = 6) were detected. The total number of FLs detected was 281; no extramedullary disease was detected. The detection rate of MM lesions between techniques was significantly different (p < 0.05): XR (89; 32%) < PET (158; 56%) < MRI (183, 65%) < LdCT alone (219; 78%) < PET/CT (277; 99%). Out of 158 FLs detected with PET, 125 (79%) were also detected with MRI. Out of 183 MM lesions detected with MRI, 125 (68%) were detected with PET; PET positivity was significantly associated with lesion size (p = 0.002). Out of 145 FLs (蠅 5 mm) detected with ldCT, the detection rate of MRI (n = 87; 60%) and PET (n = 96; 66%) was similar (p = 0.17) and significantly associated with lesion size only for MRI (p = 0.014). Whatever FLs location, the detection rate of PET and MRI was similar except for rib MM lesions for which PET was superior to MRI (p = 0.0005). Seventeen osteolytic rib lesions detected with PET were not detected with MRI, of which only one corresponded to a pathologic fracture. At the patient’s level, the diagnosis of MM was based on biological data in 7/12 patients. For the 5 remaining patients, MM diagnosis required imaging. PET/CT and ldCT alone correctly identified bone involvement in all 5 patients; MRI would have missed the correct MM diagnosis in 3 patients (2 with diffuse pattern only and one with 1 FL); WBXR would have missed MM diagnosis in 1/5 patient (one pelvic FL missed). Conclusions The MM lesion detection rate of PET/CT was superior to ldCT alone and MRI, respectively. At the patient’s level, the accuracy of PET/CT and CT alone was superior to MRI and WB-XR for the diagnosis of MM. [less ▲]

Detailed reference viewed: 26 (0 ULiège)
Full Text
Peer Reviewed
See detailLong-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.
JASPERS, Aurélie ULiege; Baron, Frédéric ULiege; Maertens, Johan et al

in American Journal of Hematology (2015), 90(7), 133-4

Detailed reference viewed: 33 (7 ULiège)
Full Text
Peer Reviewed
See detailBHS guidelines for the treatment of Burkitt lymphoma
BONNET, Christophe ULiege; Janssens, A.; Wu, KL. et al

in Belgian Journal of Hematology (2015), 6(2), 61-69

Burkitt lymphoma (BL) is a rare but very aggressive non-Hodgkin’s lymphoma characterized by an isolated translocation t(8;14)(q24;q32). The sporadic form is the subentity most frequently encountered in ... [more ▼]

Burkitt lymphoma (BL) is a rare but very aggressive non-Hodgkin’s lymphoma characterized by an isolated translocation t(8;14)(q24;q32). The sporadic form is the subentity most frequently encountered in our country. Diagnosis and initial work-up must be completed rapidly to start treatment as soon as possible. Positron emission tomography (PET) scan is useful for initial staging and to evaluate the chemosensitivity of the tumor during and after treatment. After debulking, it is recommended to add rituximab to chemotherapy. Currently intensive short-cycle chemotherapies (ISCC) and low intensity chemotherapies (LIC) are two valuable options. Radiotherapy is not indicated except in case of central nervous system involvement. Patients achieving complete remission must be followed carefully during the first year to detect recurrence of the disease. More than 80% of patients sustain their remission one year following initial treatment and are considered cured. For patients in partial remission or with chemosensitive relapse, autologous stem cell transplantation is recommended following re-induction with non-cross-resistant polychemotherapy. Monitoring complete blood counts and cognitive functions is important to detect late toxicity of the applied therapies. [less ▲]

Detailed reference viewed: 124 (15 ULiège)
Full Text
Peer Reviewed
See detailHaemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency
SID, Sélim ULiege; Dugauquier, Christophe; DE PRIJCK, Bernard ULiege et al

in Belgian Journal of Hematology (2015), 6(2), 74-78

We present a patient with Burkitt's lymphoma who suffered a severe haemolytic crisis after treatment with rasburicase. This case report underlines the high incidence of glucose-6-phosphate dehydrogenase ... [more ▼]

We present a patient with Burkitt's lymphoma who suffered a severe haemolytic crisis after treatment with rasburicase. This case report underlines the high incidence of glucose-6-phosphate dehydrogenase deficiency in some ethnic groups and the importance of a detailed patient and family history before starting treatment, even in case of emergency. Glucose-6-phosphate dehydrogenase is an essential enzyme since it makes the synthesis of NADPH + H from NADP possible, which determines the reducing power (NADPH) of the cell. Every defect in this physiological process, notably glucose-6-phosphate dehydrogenase deficiency, may thus result simultaneously with the use of rasburicase in acute or chronic haemolysis according to the importance of the deficiency. Management is based on stopping the incriminated drug and on supportive therapy consisting of administering packed red blood cells if the anaemia is poorly tolerated. [less ▲]

Detailed reference viewed: 22 (4 ULiège)
Full Text
See detailLeucémie myéloblastique aiguë : sécrétion paranéoplasique de GH et de PRL ?
VALDES SOCIN, Hernan Gonzalo ULiege; Potorac, Iulia ULiege; DE PASQUAL, Aurelie ULiege et al

in Abstract book - Annales d'Endocrinologie : 31ème Congrès de la Société Françaose d'Endocrinologie, Lyon 5-8 novembre 2014 (2014, October)

Detailed reference viewed: 29 (7 ULiège)
Full Text
Peer Reviewed
See detailHemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency.
SID, Sélim ULiege; Dugauquier, D.; DE PRIJCK, Bernard ULiege et al

in Belgian Journal of Hematology (2014)

Detailed reference viewed: 52 (9 ULiège)
See detailAlliance diagnostique et thérapeutique contre les mycoses invasives
DE PRIJCK, Bernard ULiege; HAYETTE, Marie-Pierre ULiege; MISTRETTA, Virginie ULiege

Scientific conference (2013, December 19)

Detailed reference viewed: 30 (10 ULiège)
Full Text
Peer Reviewed
See detailDiagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.
CAERS, Jo ULiege; Vekemans, Marie-Christiane; Bries, Greet et al

in Annals of Medicine (2013), 45

The prevalence of monoclonal gammopathy of undetermined significance (MGUS) is generally estimated at 3.4% in the general population over 50 years, and its incidence increases with age. MGUS represents a ... [more ▼]

The prevalence of monoclonal gammopathy of undetermined significance (MGUS) is generally estimated at 3.4% in the general population over 50 years, and its incidence increases with age. MGUS represents a preneoplastic entity that can transform into multiple myeloma or other lymphoproliferative disorders. The risk of malignant transformation is estimated at 1% per year and persists over time. Predictors of malignant transformation have been identified such as the heavy chain isotype, the monoclonal component level, increasing levels of M-protein during the first years of follow-up, bone marrow plasmocytosis, dosage of serum free light chains, the presence of immunophenotypic abnormal plasma cells, aneuploidy and the presence of circulating plasma cells. Prognostic scores that combine certain of these factors have been proposed and allow the identification of high-risk patients. Their use could assist in tailoring the care for each patient, based on his/her risk profile. [less ▲]

Detailed reference viewed: 80 (7 ULiège)
Full Text
Peer Reviewed
See detailTreatment of peripheral T-cell lymphomas: recommendations of the Belgian Hematological Society (BHS).
Van Obbergh, F.; Van Hoof, A.; Verhoef, G. et al

in Belgian Journal of Hematology (2013), 4 (3)

The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each ... [more ▼]

The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each panellist's expert provided interpretation of the evidence, based on literature review and personal experience. The available evidence was systematically discussed prior to formulating recommendations. A systematic approach to obtain consensus of expert opinion was used. After each meeting, the draft guideline was circulated to all experts for comment and approval. The present guidelines focus on general management of peripheral T-cell lymphomas with special emphasis on more specific disease-adapted stratégies. [less ▲]

Detailed reference viewed: 49 (5 ULiège)
Full Text
Peer Reviewed
See detailChimiothérapie, immunodépression et cancers secondaires : rapport d'un cas clinique
COLLINS, Patrick ULiege; Vijgen, S.; DE PRIJCK, Bernard ULiege et al

in Revue Médicale de Liège (2013), 7-8

We report the case of a multi-metastatic mucinous adenocarcinoma of the colon discovered pre-mortem in a patient with a history of multiple myeloma. This case gives the opportunity to discuss the ... [more ▼]

We report the case of a multi-metastatic mucinous adenocarcinoma of the colon discovered pre-mortem in a patient with a history of multiple myeloma. This case gives the opportunity to discuss the prognostic value of histological typing of colorectal cancer and secondary neoplasms to chemotherapy and/or immunodepression. [less ▲]

Detailed reference viewed: 99 (12 ULiège)
Full Text
Peer Reviewed
See detailLeucémie myélomonocytaire chronique : diagnostic et thérapeutique
HAFRAOUI, Kaoutar ULiege; DE PRIJCK, Bernard ULiege; Beguin, Yves ULiege

in Revue Médicale Suisse (2013), 9

Chronic myelomonocytic leukemia (CMML) is a disease typically of the elderly. It is suspected when monocytosis reaches IOOO/fil. It may be associated with «B» symptoms (fever, sweating, and weight loss ... [more ▼]

Chronic myelomonocytic leukemia (CMML) is a disease typically of the elderly. It is suspected when monocytosis reaches IOOO/fil. It may be associated with «B» symptoms (fever, sweating, and weight loss) but also visceral, skin and autoimmune complications. Current treatment strategies aim at reducing the symptoms and have no curative goals. In this context hypomethylating agents have shown a good efficacy. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option but remains difficult to perform in elderly patients population, even if transplantation with a reduced intensity conditioning has reduced the risks. A new prognostic scoring helps to recognize the patients with poor prognosis and to better selected candidates for the HSCT. [less ▲]

Detailed reference viewed: 217 (3 ULiège)
Full Text
Peer Reviewed
See detailDarbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial
BEGUIN, Yves ULiege; Maertens, Johan; DE PRIJCK, Bernard ULiege et al

in American Journal of Hematology (2013), 88

We conducted a randomized study analyzing the impact of darbepoetin alfa (DA) administration with or without intravenous (i.v.) iron on erythroid recovery after autologous hematopoietic cell ... [more ▼]

We conducted a randomized study analyzing the impact of darbepoetin alfa (DA) administration with or without intravenous (i.v.) iron on erythroid recovery after autologous hematopoietic cell transplantation (HCT). Patients were randomized between no DA (Arm 1), DA 300 lg every 2 weeks starting on Day 28 after HCT (Arm 2), or DA plus i.v. iron 200 mg on Days 28, 42, and 56 (Arm 3). The proportion achieving complete hemoglobin (Hb) response within 18 weeks (primary end point) was 21% in Arm 1 (n524), 79% in Arm 2 (n525), and 100% in Arm 3 (n523; P < 0.0001). Erythropoietic response was shown to be significantly higher in Arm 3 (n546) than in Arm 2 (n550; P50.008), resulting in lower DA use, reduced drug costs, and improved quality of life scores, but the effect on transfusions was not significant. In multivariate analysis, DA administration (P< 0.0001), i.v. iron administration (P50.0010), high baseline Hb (P< 0.0001), and low baseline creatinine (P50.0458) were independently associated with faster achievement of complete Hb response. In conclusion, DA is highly effective to ensure full erythroid reconstitution after autologous HCT when started on Day 28 post-transplant. I.v. iron sucrose further improves erythroid recovery. [less ▲]

Detailed reference viewed: 42 (4 ULiège)
Full Text
Peer Reviewed
See detailSpontaneous pneumomediastinum caused by bleomycin-induced pneumonitis
FRUSCH, Nicolas ULiege; SERVAIS, Sophie ULiege; DE PRIJCK, Bernard ULiege et al

in Acta Clinica Belgica (2012)

We report the case of a 24-yr-old woman treated for lymphoma who developed bleomycin-induced intersitial pneumonia. This interstitial pneumonia was complicated by spontaneous pneumomediastinum ... [more ▼]

We report the case of a 24-yr-old woman treated for lymphoma who developed bleomycin-induced intersitial pneumonia. This interstitial pneumonia was complicated by spontaneous pneumomediastinum. Pneumomediastinum is an unfrequent side effect of high dose bleomycin-induced pneumonitis (BIP) and we describe the first case occurring with low-dose of bleomycin. [less ▲]

Detailed reference viewed: 31 (3 ULiège)
Full Text
Peer Reviewed
See detailPanhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma
Malaise, Olivier ULiege; FRUSCH, Nicolas ULiege; BECK, Emmanuel ULiege et al

in Leukemia & Lymphoma (2012), 53(12), 2515-16

Detailed reference viewed: 44 (10 ULiège)
Full Text
Peer Reviewed
See detailPrise en charge du lymphome B diffus à grandes cellules en 2012
Bonnet, Christophe ULiege; DE PRIJCK, Bernard ULiege; LEJEUNE, Marie ULiege et al

in Revue Médicale Suisse (2012), 8

Diffuse Large B Cells Lymphoma (DLBCLI is the mast comman non-Hodgkin Iymphoma and comprises a large numberof different entities with different clinico-pathological characteristics. The role of positron ... [more ▼]

Diffuse Large B Cells Lymphoma (DLBCLI is the mast comman non-Hodgkin Iymphoma and comprises a large numberof different entities with different clinico-pathological characteristics. The role of positron emission tomography is essential dudog the Ini tial staging and post treatment assessment, and potentially at early or mid-treatmentevaluation of response. First-line therapy comprises immuno-chemotherapy with rituximab and different cytotox ic agents that differforcomponents, dosages and frequency of administration taking worldwlderecognized pre-treatment prognostic variables into account. After relapse, peripheral blood stem cells transplantation remains the only chance of cu re. This review attempts to summarize the current state of our knowledge by highlighting the leads pursued to further improve current therapeutic results. [less ▲]

Detailed reference viewed: 116 (15 ULiège)
Full Text
Peer Reviewed
See detailPrimary central nervous system lymphoma in a patient treated with Natalizumab.
Phan-Ba, Rémy ULiege; Bisig, Bettina ULiege; Deprez, Manuel ULiege et al

in Annals of Neurology (2011), 69(6), 1060-1

Detailed reference viewed: 84 (15 ULiège)
Full Text
Peer Reviewed
See detailLymphome du manteau : prise en charge 2011
Bonnet, Christophe ULiege; CAERS, Jo ULiege; DE PRIJCK, Bernard ULiege et al

in Revue Médicale Suisse (2011), 7

Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14 ... [more ▼]

Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14, avec surexpression de la cycline D1. Le traitement de première ligne du sujet jeune associe trois cures de R-CHOP21 alternées avec trois cures de R-DHAP21, suivies d'une autogreffe conditionnée par irradiation corporelle totale, cyclophosphamide et aracytine. Le sujet de plus de 65 ans peut bénéficier de huit cures de R-CHOP21. L'intérêt du traitement de maintenance est en cours d'évaluation. L'allogreffe de cellules souches hématopoïétiques offre une chance de guérison aux patients en rechute en bon état général. Les traitements ciblés permettront une amélioration du pronostic de cette maladie. [less ▲]

Detailed reference viewed: 115 (5 ULiège)
Full Text
Peer Reviewed
See detailPrise en charge actuelle des syndromes myélodysplasiques
CAERS, Jo ULiege; BONNET, Christophe ULiege; GRAUX, Carlos et al

in Revue Médicale Suisse (2011), 7

Detailed reference viewed: 39 (10 ULiège)